Interní Med. 2001; 3(9): 16-22

Standard, doporučení nebo možný postup při předpisu hormonální substituční léčby?

doc. MUDr. Taťána Rešlová CSc
Porodnická a gynekologická klinika, LF UK a FN v Hradci Králové

Keywords: perimenopause, postmenopause, hormone replacement therapy.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rešlová T. Standard, doporučení nebo možný postup při předpisu hormonální substituční léčby? Interní Med. 2001;3(9):16-22.

Hormonální substituční léčba (ERT/HRT) je pro většinu postmenopauzálních žen účinným řešením akutních, subakutních a chronických projevů estrogenního deficitu. S cílem sjednotit postup lékařů různých odborností je v předloženém článku popsán návrh rozhodovacího postupu pro předepsání ERT/HRT.

Standard, giudelines or options for the use of hormone replacement therapy?

Replacement therapy in the form of estrogen alone (ERT) or estrogen combined with progestogen (HRT) offers both short- and long-term benefits to the majority of postmenopausal women. The purpose of this article is to provide a decision tree that physicians from diverse disciplines can use to structure their decision of whether to recommend ERT/HRT.

Download citation

References

  1. A decision tree for the use of estrogen replacement therapy or hormone replacement therapy in postmenopausal women: Consensus opinion of The North American Menopause Society. Menopause, 7, 2000, s. 76-86. Go to PubMed...
  2. Achieving long-term continuance of menopausal ERT/HRT: Consensus opinion of the North American Menopause Society. Menopause, 5, 1998, s. 69-76. Go to PubMed...
  3. Blumenthal, R.S., Post, W.S.: HERS invisited: is postmenopausal hormone replacement therapy cardioprotective? Menopause Manage, 8, 1999, s. 19-20.
  4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet, 350, 1997, s. 1047-1059. Go to original source...
  5. Creasman, W.T.: Estrogen replacement therapy: is previously treated cancer a contraindication? Obstet Gynecol, 77, 1991, s. 308-312. Go to original source... Go to PubMed...
  6. Eddy, D.: Designing a practice policy: standards, guidelines, and options. JAMA, 263, 1990, s. 3077-3084. Go to original source... Go to PubMed...
  7. Grady, D., Cummings, S. R., Petitti, D., et al.: Guidelines for counselling postmenopausal women about preventive hormone therapy. Ann Intern Med., 117, 1992, s. 1038-1041. Go to original source... Go to PubMed...
  8. Grady, D., Rubin, S. M., Petitti, D. B., et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med, 117, 1992, s. 1016-1037. Go to original source... Go to PubMed...
  9. Grady, D., Wenger, N. K., Herrington, D., et al.: Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann Intern Med, 132, 2000, s. 689-696. Go to original source... Go to PubMed...
  10. Grundy, S. M., Balady, G. J., Criqui, M. H., et al.: Guide to primary prevention of cardiovascular diseases. Circulation, 95, 1997, s. 2329-2331. Go to original source... Go to PubMed...
  11. Hill, D. A., Weiss, N. S., Beresford, S. A. A., et al.: Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol, 183, 2000, s 1456-1461. Go to original source... Go to PubMed...
  12. McKinney, K. A., Thompson, W.: A practical guide to prescribing hormone replacement therapy. Drugs, 56, 1998, s. 49-57. Go to original source... Go to PubMed...
  13. Rešlová, T.: Vliv estrogenů na patologickou transformaci endometria v klimakteriu. Praha, Galén 1999, s 56-59.
  14. The North American Menopause Society develops consensus opinions. Menopause, 5, 1998, s. 67-68. Go to PubMed...
  15. World Health Scientific Group on Research on the Menopause in the 1990s. WHO Technical Report Series No. 866. Geneva: World Health Organisation, 1996, s. 12-14.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.